Eli Lilly’s first oral GLP-1 pill launches in UAE through Metabolic partnership

A major shift in obesity treatment is happening in the UAE. Metabolic has become the first healthcare provider outside the United States to offer Foundayo, Eli Lilly's newly FDA-approved oral GLP-1 medication for weight loss.

The timing is significant. Metabolic integrated the daily pill into its treatment protocols within weeks of FDA approval, with supplies expected in the first week of May. The company plans to use Foundayo as a maintenance option for patients transitioning off injectable GLP-1 treatments.

How does it work?

Foundayo (orforglipron) breaks new ground as the first daily oral GLP-1 approved for weight management without food, water, or timing restrictions. The pill works differently from existing injectable therapies in several key ways:

• No injections required - eliminates needle-related hesitation and injection fatigue
• Daily oral dosing that fits into normal routines
• No dietary restrictions around timing
• Travel-friendly format
• Six different dose levels available for personalized treatment

Clinical data shows the medication delivers meaningful weight loss while being psychologically and practically easier for many patients to maintain long-term.

Why does it matter?

The real challenge in obesity treatment isn't initial weight loss - it's keeping the weight off. Research shows up to 70% of patients regain weight after stopping GLP-1 injections, particularly when they lack structured maintenance programs.

Dr Ihsan Almarzooqi, Co-Founder and Managing Director of Metabolic, explains the gap: "Real-world evidence shows most patients struggle to maintain weight loss after intensive injectable therapy. Without structured maintenance, patients often drift back to baseline."

Foundayo addresses this problem by providing:

• A structured "off-ramp" from intensive injectable therapy
• Lower-burden maintenance treatment option
• Better treatment adherence due to convenience
• Sustained metabolic outcomes over time

Metabolic's own data supports this approach. Their 2025 Outcomes Report shows 52.2% of patients lost more than 10% of body weight after 12 months, with better muscle mass preservation compared to other providers.

The context

This launch represents more than just a new medication option. It reflects a broader shift in how obesity is treated - from short-term weight loss to long-term metabolic health management.

Metabolic treats obesity as a complex metabolic disease rather than a willpower problem. Their approach combines the new oral medication with:

• Continuous remote monitoring
• Biomarker tracking
• Behavioral support
• Lifestyle optimization
• AI-enabled risk assessment

The company holds accreditation from three major healthcare organizations: the International Consortium of Health Outcome Measures (ICHOM), the College of American Pathologists (CAP), and Joint Commission International (JCI).

The UAE market's priority status for Eli Lilly is evident in the quick availability of Foundayo. This positions the region as an early adopter of advanced obesity treatments, potentially setting new standards for metabolic care globally.